5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one

• ChemBase编号: 1055
• 分子式: C22H24ClN5O2
• 平均质量: 425.91126
• 单一同位素质量: 425.16185271
• SMILES: Clc1cc2[nH]c(=O)n(C3CCN(CC3)CCCn3c4c([nH]c3=O)cccc4)c2cc1
• Canonical SMILES: Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2
• InChI: InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
• InChIKey: FGXWKSZFVQUSTL-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
• IUPAC传统名: motilium
• 商标名: Motilium; Nauzelin; Lopac-D-122
• 别名: Domperidone; Motilium; Motillium; Motinorm; Costi; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; Domperidone

登记号

• CAS号: 57808-66-9
• EC号: 260-968-7
• MDL号: MFCD00069256
• PubChem SID: 160964518; 24277911; 46508314
• PubChem CID: 3151
• CHEBI ID: 31515
• ATC码: QP51AX24; A03FA03
• CHEMBL: 219916
• Chemspider ID: 3039
• DrugBank ID: DB01184
• IUPHAR配体索引: 965
• KEGG ID: D01745
• 美国药典/FDA物质标识码: 5587267Z69
• 维基百科标题: Domperidone

理论计算性质

JChem

• Acid pKa: 12.524702
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): 1.3633938
• LogD (pH = 7.4): 2.746269
• Log P: 2.900103
• 摩尔折射率: 119.3737 cm^3
• 极化性: 44.200592 Å^3
• 极化表面积: 67.92 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.7
• LOG S: -3.66
• 溶解度: 9.25e-02 g/l

分子性质

理化性质

• 溶解度: 0.1 M HCl: soluble; 0.1 M NaOH: slightly soluble; 0.986 mg/L; DMSO: >10 mg/mL; H2O: insoluble
• 外观: white powder
• 疏水性(logP): 2.4

安全信息

• 保存条件: -20°C; Room Temperature (15-30°C)
• RTECS编号: DE2275900
• 欧盟危险性物质标志: 有毒(Toxic) (T); 有害性(Harmful) (Xn)
• 联合国危险货物编号: 2811
• 德国WGK号: 3
• 联合国危险货物等级: 6.1
• 联合国危险货物包装类别(PG): II
• 澳大利亚Hazchem: 2XE
• 危险公开号: 63-62; R:25
• 安全公开号: 26-36; S:28-36/37/39-45-53
• 欧盟危险货物分类: T2
• 欧盟危险识别号(EUHIN): 6.1B
• 美国ERG指导号: 154
• GHS危险品标识: GHS08
• GHS警示词: Warning
• GHS危险声明: H361
• GHS警示性声明: P281
• 个人保护装置: Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges

药理学性质

• 给药途径: Oral, intravenous, rectal
• 生物利用度: High
• 排泄: Breast milk, renal
• 半衰期: 7 hours
• 代谢: Hepatic and intestinal (first-pass)
• 蛋白结合率: 91–93%
• 法定药品分级: Not approved for use or sale: US; prescription medicine (POM): India, Australia, Canada, Israel; Over the Counter (OTC): UK (Pharmacy only), Belgium, Egypt, Ireland, Italy, Japan, Netherlands, South Africa, Switzerland, China, Russia, Slovakia, Thailand, Malta, South Korea, and Romania
• 妊娠期药物分类: Not classified (US)
• 相关基因信息: human ... DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816), KCNH2(3757)rat ... Drd1a(24316), Drd2(24318), Drd3(29238), Htr3a(79246)

产品相关信息

• 纯度: ≥98% (HPLC)
• 成盐信息: Free Base

详细说明

DrugBank - DB01184

• Drug Groups: approved
• Description: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem]
• Indication: For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
• Pharmacology: Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
• Toxicity: Side effects include galactorrhea, gynecomastia, or menstrual irregularities.
• Affected Organisms: Humans and other mammals
• Absorption: Fast
• Half Life: 7 hours
• Protein Binding: 91%-93%
• References: Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998 May-Jun;20(3):438-53. [Pubmed]
• External Links: Wikipedia

Selleck Chemicals - S2461

Research Area: Metabolic Disease
Biological Activity:
Domperidone(Motilium) is a dopamine blocker and an antidopaminergic reagent. It blocks the action of. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting (area postrema on the floor of the fourth ventricle and rhomboid fossa). [1]References on Domperidone (Motilium)[1] http://en.wikipedia.org/wiki/Domperidone, ,

Sigma Aldrich - D122

Biochem/physiol Actions
Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic.

参考文献

• Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998 May-Jun;20(3):438-53. Pubmed
• http://en.wikipedia.org/wiki/Domperidone